The Use of Patient-Derived Explant Cultures for Predicting Breast Cancer Cell Migration Potential In Vitro

Miftahul Husna, Dimas Ramadhian Noor, Rizki Sekar Arum, Hana Qanita, Abinawanto, Anom Bowolaksono, Erwin Danil Julian, Astari Dwiranti

Abstract

Breast cancer ranks as one of the leading causes of death globally, while mortality rates due to breast cancer continue to rise. In Indonesia, breast cancer is the most common type of cancer, with women dying from breast cancer at a higher rate than men. Primary cultures play a significant role in examining the behavior of breast cancer cells. Because explant cultures can be performed directly from the primary tumor, they constitute a promising new tool for observing cell migration in cancer, including breast cancer. Nevertheless, the use of explant cultures to predict the migration of breast cancer cells has yet to be investigated. This study aims to assess the potential of the explant culture method to predict the migration ability of breast cancer cells in vitro. Tumor explants from two different patients were evaluated in this study. The explant cultures were observed for 14 days until passage, and the results were examined using a microscope. We found that BC02 cells took less than seven days to migrate from the primary tumor, while BC01 cells took 21 days. Furthermore, a mammosphere was observed in the BC02 sample. The rate of cell migration from the tissue depends on the malignant status of the tissue. In conclusion, this study suggests that explant cultures can be used to study the characteristics of cancer cell migration and its correlation with the malignancy of the original tissue.

 

Keywords: explant culture, cell migration, breast cancer, in vitro.

 

https://doi.org/10.55463/issn.1674-2974.49.5.16


Full Text:

PDF


References


MALLATH M. K., TAYLOR D. G., BADWE R. A., RATH G. K., SHANTA V., PRAMESH C. S., DIGUMARTI R., SEBASTIAN P., BORTHAKUR B. B., KALWAR A., and KAPOOR S. The growing burden of cancer in India: epidemiology and social context. The Lancet Oncology, 2014, 15(6): E205-E212. https://doi.org/10.1016/S1470-2045(14)70115-9

SUNG H., FERLAY J., SIEGEL R. L., LAVERSANNE M., SOERJOMATARAM I., JEMAL A., and BRAY F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-49. https://doi.org/10.3322/caac.21660

WIDIANA I. K., & IRAWAN H. Clinical and Subtypes of Breast Cancer in Indonesia. Asian Pacific Journal of Cancer Care, 2020, 5(4): 281-285. https://doi.org/10.31557/APJCC.2020.5.4.281-285

DILLEKÅS H., ROGERS M. S., and STRAUME O. Are 90% of deaths from cancer caused by metastases? Cancer Medicine, 2019, 8(12): 5574-5576. https://doi.org/10.1002/cam4.2474

WANG Y., LIU J., YING X., LIN P. C., and ZHOU B. P. Twist-mediated epithelial-mesenchymal transition promotes breast tumor cell invasion via inhibition of hippo pathway. Scientific Reports, 2016, 6(1): 24606. https://doi.org/10.1038/srep24606

LACHAT C., PEIXOTO P., and HERVOUET E. Epithelial to Mesenchymal Transition History: From Embryonic Development to Cancers. Biomolecules, 2021, 11(6): 782. https://doi.org/10.3390/biom11060782

POWLEY I. R., PATEL M., MILES G., PRINGLE H., HOWELLS L., THOMAS A., KETTLEBOROUGH C., BRYANS J., HAMMONDS T., MACFARLANE M., and PRITCHARD C. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. British Journal of Cancer, 2020, 122(6): 735-44. https://doi.org/10.1038/s41416-019-0672-6

VAN HELVERT S., STORM C., and FRIEDL P. Mechanoreciprocity in cell migration. Nature Cell Biology, 2018, 20(1): 8-20. https://doi.org/10.1038/s41556-017-0012-0

MAYOR R., & ETIENNE-MANNEVILLE S. The front and rear of collective cell migration. Nature Reviews Molecular Cell Biology, 2016, 17(2): 97-109. https://doi.org/10.1038/nrm.2015.14

ESPARZA-LÓPEZ J., MARTÍNEZ-AGUILAR J. F., and IBARRA-SÁNCHEZ M. D. Deriving primary cancer cell cultures for personalized therapy. Revista de Investigación Clínica, 2019, 71(6): 369-380. https://doi.org/10.24875/ric.19002832

STANEVA R., EL MARJOU F., BARBAZAN J., KRNDIJA D., RICHON S., CLARK A. G., and VIGNJEVIC D. M. Cancer cells in the tumor core exhibit spatially coordinated migration patterns. Journal of Cell Science, 2019, 132(6): jcs220277. https://doi.org/10.1242/jcs.220277

STANEVA R., BARBAZAN J., SIMON A., VIGNJEVIC D. M., and KRNDIJA D. Cell migration in tissues: explant culture and live imaging. In: GAUTREAU A. (eds.) Cell Migration. Methods in Molecular Biology, Vol. 1749. Humana Press, New York, 2018: 163-173. https://doi.org/10.1007/978-1-4939-7701-7_13

LEBERT J. M., LESTER R., POWELL E., SEAL M., and MCCARTHY J. Advances in the systemic treatment of triple-negative breast cancer. Current Oncology, 2018, 25(s1): 142-150. https://doi.org/10.3747/co.25.3954

AL-ZAWI A. S., SYED A., SALIH A., IDAEWOR P., ELAMASS M., and KAPTUREK A. Evaluation of the correlation between Ki-67 proliferative index and the histopathological grade of invasive neoplasms in early breast cancer aged < 70 years of age: a review of 300 cases. Medical Research Journal, 2021, 6(1): 4-7. https://doi.org/10.5603/MRJ.a2020.0049

KIM D. H., XING T., YANG Z., DUDEK R., LU Q., and CHEN Y. H. Epithelial-mesenchymal transition in embryonic development, tissue repair and cancer: a comprehensive overview. Journal of Clinical Medicine, 2017, 7(1): 1. https://doi.org/10.3390/jcm7010001

SERRANO-GOMEZ S. J., MAZIVEYI M., and ALAHARI S. K. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Molecular Cancer, 2016, 15(1): 18. https://doi.org/10.1186/s12943-016-0502-x

ZOU T., LAN M., LIU F., LI L., CAI T., TIAN H., and CAI Y. Emodin-loaded polymer-lipid hybrid nanoparticles enhance the sensitivity of breast cancer to doxorubicin by inhibiting epithelial-mesenchymal transition. Cancer Nanotechnology, 2021, 12(1): 22. https://doi.org/10.1186/s12645-021-00093-9

HUANG S., YUAN N., WANG G., WU F., FENG L., LUO M., LI M., LUO A., ZHAO X., and ZHANG L. Cellular communication promotes mammosphere growth and collective invasion through microtubule‑like structures and angiogenesis. Oncology Reports, 2018, 40(6): 3297-3312. https://doi.org/10.3892/or.2018.6778

AYOB A. Z., & RAMASAMY T. S. Cancer stem cells as key drivers of tumor progression. Journal of Biomedical Science, 2018, 25(1): 20. https://doi.org/10.1186/s12929-018-0426-4

TOMITA H., TANAKA K., TANAKA T., and HARA A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget, 2016, 7(10): 11018. https://doi.org/10.18632/oncotarget.6920

PAULA A. D., & LOPES C. Implications of different cancer stem cell phenotypes in breast cancer. Anticancer Research, 2017, 37(5): 2173-2183. https://doi.org/10.21873/anticanres.11552

SHIBUE T., & WEINBERG R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Reviews Clinical Oncology, 2017, 14(10): 611-629. https://doi.org/10.1038/nrclinonc.2017.44

YANG F., XU J., TANG L., and GUAN X. Breast cancer stem cell: the roles and therapeutic implications. Cellular and Molecular Life Sciences, 2017, 74(6): 951-966. https://doi.org/10.1007/s00018-016-2334-7


Refbacks

  • There are currently no refbacks.